WO2009145557A3 - Use of physcion-8-o-beta-d-glucopyranoside or physcion for promoting osteoblast activity - Google Patents

Use of physcion-8-o-beta-d-glucopyranoside or physcion for promoting osteoblast activity Download PDF

Info

Publication number
WO2009145557A3
WO2009145557A3 PCT/KR2009/002802 KR2009002802W WO2009145557A3 WO 2009145557 A3 WO2009145557 A3 WO 2009145557A3 KR 2009002802 W KR2009002802 W KR 2009002802W WO 2009145557 A3 WO2009145557 A3 WO 2009145557A3
Authority
WO
WIPO (PCT)
Prior art keywords
physcion
glucopyranoside
beta
osteoblast activity
bone formation
Prior art date
Application number
PCT/KR2009/002802
Other languages
French (fr)
Other versions
WO2009145557A2 (en
Inventor
Seong Hwan Kim
Yong Ki Min
Su-Ui Lee
Young Sup Kim
Hanbok Kwak
Original Assignee
Korea Research Institute Of Chemical Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute Of Chemical Technology filed Critical Korea Research Institute Of Chemical Technology
Publication of WO2009145557A2 publication Critical patent/WO2009145557A2/en
Publication of WO2009145557A3 publication Critical patent/WO2009145557A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Physcion-8-O-β-D-glucopyranoside or physcion of the present invention potently enhances osteoblastic differentiation, mineralization, and bone formation. Therefore, the inventive use of physcion-8-O-β-D-glucopyranoside or physcion can be advantageously used for enhancing bone formation in a mammal suffering from a bone formation-related disease such as osteoporosis, fracture, periodontal disease, and bone growth disorder.
PCT/KR2009/002802 2008-05-27 2009-05-27 Use of physcion-8-o-beta-d-glucopyranoside or physcion for promoting osteoblast activity WO2009145557A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080049090A KR100999458B1 (en) 2008-05-27 2008-05-27 Pharmaceutical composition for promoting osteoblast activity comprising physcion-8-o-?-d-glucopyranoside or physcion
KR10-2008-0049090 2008-05-27

Publications (2)

Publication Number Publication Date
WO2009145557A2 WO2009145557A2 (en) 2009-12-03
WO2009145557A3 true WO2009145557A3 (en) 2010-03-04

Family

ID=41377780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002802 WO2009145557A2 (en) 2008-05-27 2009-05-27 Use of physcion-8-o-beta-d-glucopyranoside or physcion for promoting osteoblast activity

Country Status (2)

Country Link
KR (1) KR100999458B1 (en)
WO (1) WO2009145557A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084871A (en) * 2001-05-04 2002-11-13 알앤엘생명과학주식회사 Composition comprising an extract of cassia obtusifolia for hormone replacement theraphy
KR20070066104A (en) * 2005-12-21 2007-06-27 한국화학연구원 Composition for antihypertensive effect comprising a rhei rhizoma extract or active compounds isolated therefrom
WO2008044848A1 (en) * 2006-10-10 2008-04-17 Digital Biotech Co., Ltd A composition comprising an extract of rhei rhizoma or physcion compound isolated therefrom for treating or preventing cognitive dysfunction and the use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084871A (en) * 2001-05-04 2002-11-13 알앤엘생명과학주식회사 Composition comprising an extract of cassia obtusifolia for hormone replacement theraphy
KR20070066104A (en) * 2005-12-21 2007-06-27 한국화학연구원 Composition for antihypertensive effect comprising a rhei rhizoma extract or active compounds isolated therefrom
WO2008044848A1 (en) * 2006-10-10 2008-04-17 Digital Biotech Co., Ltd A composition comprising an extract of rhei rhizoma or physcion compound isolated therefrom for treating or preventing cognitive dysfunction and the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIN D ET AL.: "Chemical constituents ofPheum wittrochii Lundstr(I).", ZHONGGUO ZHOUNG YAO ZA ZHI., vol. 23, no. 7, July 1998 (1998-07-01), pages 416 - 418, 447 *
NARENDRA P. SINGH ET AL.: "High-performance thin layer chromatography method for quantitative determination of four major anthraquinone derivatives in Rheum emodi.", JOURNAL OF CHROMATOGRAPHY A., vol. 1077, no. 2, 10 June 2005 (2005-06-10), pages 202 - 206 *

Also Published As

Publication number Publication date
KR100999458B1 (en) 2010-12-09
KR20090123152A (en) 2009-12-02
WO2009145557A2 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
EP3205647A3 (en) 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
HK1137366A1 (en) Pharmaceutical compositions comprising activin-actriia antagonists and use thereof in preventing or treating multiple myeloma
WO2010003696A3 (en) Bone implant application
DE602008006293D1 (en) System for reducing the wear of joint surface implants
CN102036649A8 (en) Arginine salt and its purposes for treating mouth disease
MY158438A (en) Antibodies against human angiopoietin 2
EP2414043A4 (en) Bmp-alk3 antagonists and uses for promoting bone growth
UA108198C2 (en) Substituted 2-acetamido-5-aryl-l, 2,4-triazolones and their use
WO2008148873A3 (en) Hydroxyproline compositions and uses thereof
ZA201403596B (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
EP2504001B8 (en) Combination for the treatment of radiation- or chemotherapy-induced mucositis
WO2011008773A3 (en) Mesenchymal stem cell differentiation
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
IN2012DN03178A (en)
WO2010144477A3 (en) Sulfonylurea modulators of endothelin receptor
EP2134300A4 (en) Calcium phosphate cements comprising autologous bone
EP2207555A4 (en) Novel compounds for the treatment or alleviation of edema, and methods for their use
FR2871365B1 (en) IMPLANT FOR THE TREATMENT OF THE RECTOCELE OR CYSTOCELE
WO2010141811A3 (en) Compounds and methods for treating bone disorders and controlling weight
WO2010098583A2 (en) Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
EP2575912A4 (en) Glassy calcium phosphate particulates, coatings and related bone graft materials
WO2007103584A3 (en) Polyamides for treating human papilloma virus
EP2502989A4 (en) Implant composition for the regeneration of neural tissue, process of preparation and uses thereof
WO2011029639A3 (en) Compounds and methods for treating neoplasia
WO2010015938A3 (en) Use of agonists of integrin alpha 5 for inducing the osteogenic differentiation of mesenchymal stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09755022

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09755022

Country of ref document: EP

Kind code of ref document: A2